CA-IMAGO-BIOSCIENCES
30.7.2020 14:02:16 CEST | Business Wire | Press release
Imago BioSciences, Inc . (“Imago”), a private clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that the European Medicines Agency (EMA) granted access to its PRIME (PRIority MEdicines) scheme for IMG-7289 (bomedemstat), a lysine-specific demethylase-1 (LSD1) inhibitor, for the treatment of intermediate-2 and high-risk patients with myelofibrosis who have become intolerant of, resistant to, or are ineligible for a Janus Kinase (JAK) inhibitor. IMG-7289 is being evaluated in an open-label Phase 2 clinical trial (www.myelofibrosisclinicalstudy.com ) for the treatment of advanced myelofibrosis, a bone marrow cancer that interferes with the production of blood cells.
The PRIME initiative was launched by the EMA in 2016 to provide proactive and enhanced support to the developers of promising medicines with the view of accelerating their evaluation to reach patients faster. To be eligible for PRIME, a medicine must address an unmet medical need and show potential clinical benefit based on early trial data. Myelofibrosis is a progressive cancer in which bone marrow is gradually replaced by fibrous, scar-like tissue impairing the production of blood cells for which treatment options are limited.
"We are excited to receive PRIME designation for IMG-7289, our first LSD1 inhibitor in the clinic,” said Hugh Young Rienhoff, Jr., M.D., CEO of Imago BioSciences. “We intend to work closely with the EMA to optimize our development plans and help bring IMG-7289 to patients as quickly as possible. Myelofibrosis remains a major unmet medical need and IMG-7289 represents a potential new option for patients who don’t benefit from the current standard of care.”
The EMA reviewed IMG-7289 non-clinical and clinical data from the ongoing Phase 2 study, which demonstrated improvements in symptom scores, spleen volumes, anemia and bone marrow fibrosis. Data presented at the 25th European Hematology Association (EHA) Annual Congress demonstrated that IMG-7289 was well tolerated with no dose-limiting toxicities or safety signals. The Phase 2b study is actively enrolling in the U.S., U.K., and E.U.
About IMG-7289 (Bomedemstat)
IMG-7289 is a small molecule invented and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be essential for maturation of blood cells and vital to neoplastic stem/progenitor bone marrow cells. In non-clinical studies, IMG-7289 demonstrated robust in vivo anti-tumor efficacy as a single agent and in combination with other chemotherapeutic agents across a range of myeloid malignancies including leukemia and myeloproliferative neoplasms such as myelofibrosis. IMG-7289 is an investigational agent currently being evaluated in several ongoing clinical trials (ClinicalTrials.gov Identifier: NCT03136185 , NCT04254978 , NCT04262141 , NCT04081220 ). IMG-7289 has FDA Orphan Drug and Fast Track Designation for both the treatment of myelofibrosis and essential thrombocythemia, and Orphan Drug Designation for treatment of acute myeloid leukemia.
About Imago BioSciences
Imago BioSciences is a private clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics targeting epigenetic enzymes. Imago has developed a series of compounds that alter the activity and function of LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell maturation and function. Imago is advancing the clinical development of its first LSD1 inhibitor, IMG-7289, for the treatment of myeloid neoplasms including myelofibrosis, essential thrombocythemia and polycythemia vera. Imago BioSciences is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com and follow us on Twitter @ImagoBioRx , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005280/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Media Release: Jannik Sinner and Allianz Announce Multi-Year Global Partnership29.1.2026 11:04:00 CET | Press release
Jannik Sinner becomes Global Brand Ambassador of the world’s most valuable insurance brand.The partnership broadens Allianz’s established sports collaborations; the large tennis fan base worldwide will drive emotional engagement with Allianz.“We’re here to serve” captures the spirit of both partners; joint projects with The Jannik Sinner Foundation aim to support children’s future. Tennis star Jannik Sinner and Allianz Group announced a multi-year global partnership today, with the leading insurer and asset manager becoming an official partner of the four-time Grand Slam champion. Boasting approximately 300 million fans worldwide and a billion-strong ATP global fan base, tennis is the second-most popular sport behind football across Allianz key markets. A cornerstone of the collaboration is empowering children and youth through education and sport, providing them with enhanced opportunities for growth, health, and future success. This partnership also expands Allianz's involvement in s
How Aker Security Builds Control Rooms for Real-Time Decision-Making29.1.2026 10:00:00 CET | Press release
In a new case, Aker Security demonstrates how a control room built on Cyviz’ technology platform functions as the operational nerve center for decision-making, collaboration, and preparedness. In today’s security landscape, the challenge lies in aggregating, visualizing, and using large volumes of data effectively in situations where time, precision, and coordination are critical. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129578139/en/ GSOC Aker Security oversees security and preparedness for large parts of the Group, covering several thousand employees. Its services include travel security, global event and incident monitoring, crisis management, and security advisory services. "We approached Cyviz because we needed a solution that could bring everything together on a single platform, while at the same time supporting the way we actually work operationally," says Tonje Evensen Bråthen, Head of the Global Security Op
Multi-Color Corporation Initiates Implementation of Restructuring Agreement29.1.2026 07:58:00 CET | Press release
Commences Prepackaged Chapter 11 Process As Part of Previously Announced Restructuring Support Agreement to Reset Balance Sheet and Position Company for Long-Term Growth and InvestmentRestructuring Supported by CD&R and More Than Supermajority of Senior Secured Lenders Who Have Agreed to Backstop Nearly $890 Million Investment; Provides More Than $500 Million of New Liquidity Upon EmergenceAll Global Operations and Service to Customers Expected to Continue Without Interruption; All Trade Vendors and Suppliers Expected to be Paid in FullProvides for $250 Million of New Money Debtor-in-Possession Financing to Capitalize the Business Throughout the Prepackaged Chapter 11 Process Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that to implement the previously announced restructuring support agreement (the “RSA”), the Company has commenced its prepackaged Chapter 11 filing in the United States Bankruptcy Court for the District of N
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead29.1.2026 07:37:00 CET | Press release
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER);Impact of VYVANSE® Generics is Tapering OffCore Operating Profit Declined by 3.4% at both CER and AER Year to DateReported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance has been updated primarily due to the impact of VYVANSE generics. Takeda is positioned for long-term growth and has multiple late-stage programs with multibillion-dollar peak revenue potential. Follow
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty29.1.2026 07:00:00 CET | Press release
‘Wake Up To Restylane®’ is a global campaign designed to meet the rising demand for natural-looking always-on results, helping people wake up looking refreshed and rested, and reframes Restylane treatments from a clinical procedure into an always-on beauty regimen Backed by 30 years of science, the Restylane portfolio is the only hyaluronic acid (HA) range offering four distinct technologies, designed to deliver personalized natural-looking outcomes that provide contour, definition, and hydration, with HA closest to the skin’s own1-7 This launch builds on new clinical data presented at the International Master Course on Aging Science (IMCAS) World Congress 2026, confirming Restylane’s proven efficacy and versatility across multiple facial areas and the décolletage8-11 Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom